Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.56 |
| ▸ | PPARA | Q07869 | 16/20 | 0.56 |
| ▸ | PPARD | Q03181 | 5/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818678 | 0.90 | PPARG (0.46) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL978773 | 0.90 | SLC7A5 (0.62) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL6818879 | 0.87 | PPARG (0.43) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL1670312 | 0.80 | PPARA (0.69) | PPARGPPARAPPARD | |
| SCHEMBL4993002 | 0.80 | PPARA (0.69) | PPARGPPARAPPARD | |
| SCHEMBL979752 | 0.80 | SLC7A5 (0.56) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL977574 | 0.78 | SLC7A5 (0.54) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL977406 | 0.77 | PPARA (0.56) | PPARGPPARAPPARD | |
| SCHEMBL3261539 | 0.75 | PPARA (0.51) | PPARGPPARAPPARD | |
| SCHEMBL5389506 | 0.74 | PPARA (0.81) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | PPARG 46/4885PPARA 87/4885PPARD 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.